20Med Therapeutics has an open PhD position in the ITN CARTHAGO program aimed at developing non-viral gene therapy for the treatment of osteoarthritis.
Leiden, The Netherlands, October 1, 2020, 20Med Therapeutics today announced its involvement in the EC funded Horizon 2020 Marie Curie Innovative Training Network (ITN) CARTHAGO project. CARTHAGO offers 15 PhD positions with different partners across Europe. O...Read More
20Med Therapeutics expands its R&D team at the Leiden BioScience Park in The Netherlands
To support the development of its growing pipeline of mRNA based vaccines and therapeutics 20Med Therapeutics is expanding its R&D capacity by opening an additional laboratory in Leiden. Originally founded out of the University of Twente, 20Med’s research op...Read More
20Med Therapeutics appoints Allard Kaptein to Supervisory Board
RELEASED ON OCTOBER 28, 2019. ENSCHEDE, The Netherlands, Oc. 28, 2019 – 20Med Therapeutics BV, a biotechnology company developing innovative nanoparticles for delivery of RNA therapeutics today announced the appointment of Dutch biotech veteran and serial ent...Read More
20Med Therapeutics and Partners Receive Eurostars Grant for the Development of New mRNA Therapeutics for Osteoarthritis
RELEASED ON JULY 24, 2019. 20Med Therapeutics today announced with its partners Ethris GmbH, the AO Research Institute Davos and Paracelsus Medical University the receipt of a Eurostars grant to be used to further the development of a novel approach to treatin...Read More
20Med Therapeutics secures new financing for accelerated development of the 20Med Nanogel technology for the delivery of RNA therapeutics
RELEASED ON NOVEMBER 2, 2017. Please find the document here...Read More
New Horizon 2020 Project B-SMART Develops RNA-based Therapy for Neurodegenerative Diseases.
RELEASED ON FEBRUARY 1, 2017 Pleas find the document here....Read More